Poland· PL-100439164

Hepcludex

A bulevirtide product containing bulevirtidum, registered in Poland by Gilead Sciences Ireland UC. The same ATC class is registered in 14 of our 19 countries.

ATC J05AX28

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedHepcludexATCJ05AX28REGISTER NO.PL-100439164PACKS LISTED2CHECKEDSeptember 27, 2026

Where it is registered

Bulevirtide is registered in 14 of 19 countries.

Countries holding a registration under ATC J05AX28 (bulevirtide), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 10 of them publish a price we can compare per daily dose

Bulevirtide · ATC J05AX28

14 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of bulevirtide costs, country by country.

Normalised to the WHO defined daily dose (2 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Bulevirtide · price per daily dose (2 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$219.16
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Bulevirtidum
Manufacturer
Gilead Sciences Ireland UC
Country
Poland (PL)
ATC code
J05AX28
ATC class
Bulevirtide
Defined daily dose
2 mg, P
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 2

  • gtin
    04150166533716
  • gtin
    03400930211281

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/06e44fa5-3f74-4c1f-bcf3-5ffb5b023282
GET /v1/drugs/06e44fa5-3f74-4c1f-bcf3-5ffb5b023282?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Proszek do sporządzania roztworu do wstrzykiwań",
  "source": "urpl",
  "strength": "2 mg",
  "packaging": "Rpz ¦ EU/1/20/1446/001 ¦ 137227\n30 fiol. 2 mg proszku\n¦ UR/Z/4b/016/24 - 04150166533716 ¦ UR/Z/4b/106/24 - 03400930211281 ¦ UR/Z/4b/172/24 - 04150166533716 ¦ UR/Z/4b/111/25 - 04150166533716 ¦ UR/Z/4b/120/25 - 04150166533716 ¦ UR/Z/4b/219/25 - 04150166533716 ¦ UR/Z/4b/301/25 - 04150166533716 ¦ UR/Z/4b/032/26 - 04150166533716 ¦ UR/Z/4b/160/26 - 04150166533716 ¦ UR/Z/4b/242/26 - 04150166533716",
  "substance": "Bulevirtidum 2 mg",
  "common_name": "Bulevirtidum",
  "pl_product_id": "100439164",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}

See everything about bulevirtide.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.